Seminar: TRIPS, Pharmaceutical Patents, and Generic Competition in India

Το Γραφείο Μεταφοράς Τεχνογνωσίας (ΓΜΤ), σε συνεργασία με το Μεταπτυχιακό του ΓΜΤ στην καινοτομία και την επιχειρηματικότητα ΤΙΜΕ-ΜΒΕ, διοργανώνουν την Τρίτη 6 Δεκεμβρίου στις 13:00 το 4ο στην σειρά διαδικτυακό σεμινάριο του ΓΜΤ για την περίοδο 2022-2023.

Ομιλήτρια είναι η Margaret Kyle από το CERNA. 

Ο τίτλος της παρουσιάσεως είναι “TRIPS, Pharmaceutical Patents, and Generic Competition in India”

Για να συνδεθείτε ακολουθήστε τον κάτωθι σύνδεσμο: Join Zoom Meeting: https://us02web.zoom.us/j/96479541729
Meeting ID: 964 7954 1729

Abstract: Before the 1995 Trade Related Intellectual Property Rights (TRIPS) agreement, India did not allow pharmaceutical product patents. TRIPS required India (and many other developing countries) to amend patent laws to grant product patents on drugs, raising concerns among policymakers, academics, and advocacy groups that the new patent regime would hinder access to medicines. This paper assesses the impact of TRIPS on competition in India using new and updated data on patents, and exploits the precise institutional details of TRIPS implementation. We argue that a significant effect was unlikely to be immediate in India and most developing countries, and indeed may have been realized only relatively recently. When we focus on the set of drugs fully under the TRIPS regime, those that are eligible for stronger “primary” patent protection, we find large effects of patents on competition. The results are likely to be more representative of the long-run steady state impact of TRIPS in India than are previous estimates.